Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2006

View Archived Issues

Axcan Pharma reports Q4 highlights

BioAlliance cleared for phase II/III trial of doxorubicin Transdrug

Ariad presents novel oral Bcr-Abl kinase inhibitor with broad activity

Novel HDAC inhibitor shows superiority to vorinostat in vitro

Promising therapeutics for multiple myeloma presented at the ASH meeting

Snapshots of newly reported clinical trials in lymphoma

Progress in clinical developments for Loramyc and acyclovir Lauriad

Nanobody collaboration achieves first milestone

Review confirms rEV-131 findings in allergic rhinitis

Preclinical findings for carrier molecule BP-Cx-1

Pivotal studies for NM-100060 in onychomycosis begin screening

Nippon Shinyaku and Roche terminate NS-220 license agreement

FDA Joint Advisory Committee makes recommendations regarding Ketek

Advisory Committee recommends alternative phase II study for Hemopure

Pharmexa and Ichor collaborate on HER-2 DNA AutoVac

European Commission clearance for Merck KGaA's acquisition of Serono

Abbott completes acquisition of Kos

Lilly amends offer for Icos

Alliance gets French go-ahead for phase II trial of Oxygent

Enrollment completed in phase IIb study of elocalcitol in BPH

Ambrisentan NDA filed in pulmonary arterial hypertension

Astellas resubmits NDA for vernakalant hydrochloride

Orphan Therapeutics plans rolling NDA for Lucassin

Novel possible psychopharmacologic drugs identified in recent patents

Tracleer shows efficacy in mildly symptomatic PAH patients

New preclinical data on anticonvulsants

Proellex achieves statistically significant pain reduction in endometriosis

Sankyo patents novel antiplatelet agents

Novel analgesic agents imparted in recent Vertex and Gruenenthal patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...